Amyotrophic Lateral Sclerosis (ALS) is also known as Lou Gehrig’s disease. It is a progressive, rarely occurring neurological disease that mainly involves the nerve cells (neurons) which are responsible for controlling voluntary muscle movements. With time, it leads to muscle weakness, gradually affecting the functions of the body.

1. Amyotrophic Lateral Sclerosis
Competitive Landscape, Market
Insights, Epidemiology, & Market
Forecast 2025

2. • Amyotrophic Lateral Sclerosis (ALS) is also known as Lou
Gehrig’s disease. It is a progressive, rarely occurring
neurological disease that mainly involves the nerve cells
(neurons) which are responsible for controlling voluntary
muscle movements. With time, it leads to muscle weakness,
gradually affecting the functions of the body.
• Voluntary muscles produce movements like chewing,
breathing, talking, and walking.
• Amyotrophic Lateral Sclerosis belongs to a wider group of
disorders called motor neuron diseases that are caused by
gradual degeneration and death of motor neurons.
• As ALS progresses, these motor neurons tend to degenerate
and die, ceasing to send signals to muscles, which in turn
causes them to weaken.
• With disease progression, the brain’s ability to control
voluntary movement is lost.
• ALS greatly reduces an individual’s life expectancy with most
people dying within two to five years of diagnosis.
AMYOTROPHIC LATERAL SCLEROSIS(ALS)

3. REPORT HIGHLIGHTS
Information on Marketed products &
Comparative analysis of drugs in
various stages & therapeutic
assessment
Report includes guidelines for
the clinical management and
treatment algorithm for ALS
Global Market Size for ALS with special
focus on 7MM from 2015-2025
Report includes Historical and
Forecasted Sales of Marketed Drugs
Detailed historical and
forecasted global epidemiological
data with special focus on 7MM
from 2015-2025
1
2
3
4
5

4. In 2015, 5,786 incident cases
of Amyotrophic Lateral
Sclerosis were reported in the
US
The United States accounts
for the highest number of
incident cases for ALS which
is 37% of the total incidence
of ALS cases in 7MM.
Global prevalence of ALS is
expected to grow at the
CAGR of 2.3 % between 2015-
2025
KEY FINDINGS
In the United States, the
incidence of Amyotrophic Lateral
Sclerosis (ALS) is higher in males.
In the United States, the incident
cases of ALS are highest in whites
in comparison to blacks and other
races.
Sporadic type of ALS accounts for
about 95% of the total ALS cases.

5. KEY INSIGHTS
The prevalence of ALS is
expected to increase at
a CAGR of 2.3%.
Around 61 drugs are
currently in the clinical
development pipeline
Out of the total drugs 2
are in the phase III
19 drugs in phase II and
rest in phase 1, pre-clinical
and discovery phase.
2.3%
61
2
19

6. KEY PLAYERS

7. Reasons to Buy
To understand the future
market competition in
the ALS market and
Insight reviews of the key
market drivers and
barriers.
The report will help in
developing business
strategies by
understanding trends
shaping and driving the
ALS market.
Identification of strong
upcoming players in the
market will help in
devising strategies that will
help in getting ahead of
competitors.
Organize sales and
marketing efforts by
identifying the best
opportunities for ALS
globally.

8. About DelveInsight
DelveInsight, market research and
consulting firm, provides end to end
comprehensive solutions to the Life
Science Industry.
We help our customers in best decision
making through our expertise in
research & analysis and comes out with
unmatched data & forecasts
Vision
“Insight across the value chain”
to help organizations make
important business decisions
through the use and analysis of
actionable market intelligence
Mission
To be the most trusted marketing
research firm & business consulting firm
worldwide.
To be a renowned and premier data
driven solution providers among Pharma
& Biotech companies.
DelveInsight © 2017 | All rights reserved

9. Services Offered at DelveInsight
01
03
05
07
02
04
06
08
• Market Size
• Market Dynamics
• Market Assessment
• Asset Prioritization
• Brand Optimization
• Portfolio Expansion
Access over 3000+ Reports
• API
• Market & Pipeline
• Epidemiology
• Trends Analysis
• Physicians & Patients
Perception
• KOLs
• Primary Analytics
• News-Letters
• Conference Tracking
• Clinical Trials Tracking
• Competitive landscape
• Clinical Trials
• Therapeutic Assessment
• Drug Sales Forecast
• Indication Forecast
• Late Stage Pipeline
Analysis
Opportunity Assessment
• Licensing
• Market Access
• Partnership

10. Add a Slide Title - 5
Contact Us:
info@delveinsight.com
+91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight